Patrick A Baeuerle

This inventor holds 35 USPTO granted patents and 16 published patent applications and 3 EPO patents, primarily in Binding Proteins. Top assignees: Tcr2 Therapeutics Inc., Werewolf Therapeutics, Inc., Harpoon Therapeutics, Inc.. Active years: 2001-2025.

USPTO Granted Patents = 35 (Patent Applications = 16)

% Patents Active = 88.6

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 302(Granted Patents)

Location History:

Munich, DE (2007 - 2014)
Cambridge, MA (US) (2019)
South San Francisco, CA (US) (2003 - 2022)
Gauting, DE (2001 - 2024)

Company Filing History:

9 out of 10

Tcr2 Therapeutics Inc.

patents

7 out of 12

Werewolf Therapeutics, Inc.

patents

6 out of 25

Harpoon Therapeutics, Inc.

Amgen Research (Munich) Gmbh

patents

7. 1 out of 1,226

Takeda Pharmaceutical Company Limited

patents

8. 1 out of 1

Tcr2 Therabeutics Inc.

10. 1 out of 834,411

Other

patents

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Interleukin Polypeptides

Trispecific Binding Proteins

Bispecific Antibodies

TCR Reprogramming

Antigen Binding Proteins

Prostate Specific Membrane Antigen

Pharmaceutical Compositions

Drug Screens

Nuclear Hormone Receptors

Gene Expression Monitoring

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275769 - Activatable interleukin 12 polypeptides and methods of use thereof (2025-04-14),

2. 12128102 - Constrained conditionally activated binding proteins (2024-10-29),

3. 12084518 - Trispecific binding proteins and methods of use (2024-09-10),

4. 11981716 - Activatable interleukin-2 polypeptides and methods of use thereof (2024-05-14),

5. 11965012 - Compositions and methods for TCR reprogramming using fusion proteins (2024-04-23),

6. 11851491 - Compositions and methods for TCR reprogramming using fusion proteins (2023-12-26),

7. 11753475 - Bispecific-Fc molecules (2023-09-12),

8. 11535668 - Inducible monovalent antigen binding protein (2022-12-27),

9. 11535658 - Activatable interleukin-2 polypeptides and methods of use thereof (2022-12-27),

10. 11453710 - Activatable interleukin 12 polypeptides and methods of use thereof (2022-09-27),

11. 11377638 - Compositions and methods for TCR reprogramming using fusion proteins (2022-07-05),

12. 11352403 - Activatable interleukin-2 polypeptides and methods of use thereof (2022-06-07),

13. 11242376 - Compositions and methods for TCR reprogramming using fusion proteins (2022-02-08),

14. 11154617 - Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemia (2021-10-26),

15. 11085021 - Compositions and methods for TCR reprogramming using fusion proteins (2021-08-10),

Title: The Innovative Journey of Patrick A. Baeuerle

Introduction: Patrick A. Baeuerle is a renowned inventor hailing from Gauting, Germany, known for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Patrick A. Baeuerle holds several patents in the areas of immunotherapy, cancer treatment, and targeted therapies, showcasing his commitment to advancing medical science through innovation.

Career Highlights: With a distinguished career spanning over three decades, Baeuerle has held key positions in various research institutions and biotech companies, leading teams in the development of novel therapies for complex diseases.

Collaborations: Throughout his career, Patrick A. Baeuerle has collaborated with leading scientists, researchers, and pharmaceutical companies worldwide, fostering a culture of innovation and knowledge exchange in the scientific community.

Conclusion: Patrick A. Baeuerle's relentless pursuit of innovation and his passion for improving patient outcomes have solidified his reputation as a pioneering inventor in the field of biotechnology, leaving a lasting impact on the healthcare industry.